Tag Archives: Teresa Curtin & Ellen Relkin

Preamble Preemption and the Challenged Role of Failure to Warn and Defective Design Pharmaceutical Cases in Revealing Scientific Fraud, Marketing Mischief, and Conflicts of Interest

In January 2006, the Bush administration articulated a position in favor of a broad conflict preemption doctrine that would immunize pharmaceutical manufacturers from civil liability when the Food and Drug Administration (“FDA”) had previously granted permission to place a prescription … Continue reading

Posted in Articles | Tagged , , , | Leave a comment